Efficacy outcomes in patients using alefacept in the AWARE study

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue SUPPL. 3, 2009, Pages

  Landells, Ian ^{a,b,c,d,e,f,g}   Searles, Gordon ^{a,b,c,d,e,f,g}   Bissonnette, Robert ^{a,b,c,d,e,f,g}   Shear, Neil H ^{a,b,c,d,e,f,g}   Vender, Ronald ^{a,b,c,d,e,f,g}   Lui, Harvey ^{a,b,c,d,e,f,g}  

^a Nexus Clinical Research Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c INNOVADERM RESEARCH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Dermatrials Research   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; IMMUNOMODULATING AGENT; TOPICAL AGENT;

ARTICLE; BODY SURFACE; CANADA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE REGISTRY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 4 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PSORIASIS VULGARIS; REMISSION; RETREATMENT; TREATMENT DURATION; TREATMENT RESPONSE;

CANADA; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MORBIDITY; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PSORIASIS; RECOMBINANT FUSION PROTEINS; RECURRENCE; TREATMENT OUTCOME;

EID: 74349110120     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.00030     Document Type: Article

References (18)

1. Astellas Pharma Canada Inc. Amevive [product monograph]. June 1, 2006.
2. Krueger J. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002;46:1-23.
3. Lebwohl M, Christophers E, Langley R, et al, for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
4. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003;2:624-8.
5. Menter A, Cather JC, Baker D, et al. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006;54:61-3.
6. Perlmutter A, Cather J, Franks B, et al. Alefacept revisited: our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008;58:116-24.
7. Bissonnette R, Searles G, Landells I, et al. The AWARE study: methodology and baseline characteristics. J Cutan Med Surg 2009; 13 Suppl 3:113-21.
8. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003;14:158-65.
9. Wexler D, Searles G, Landells I, et al. Update on alefacept safety. J Cutan Med Surg 2009;13 Suppl 3:139-47.
10. Vaishnaw AK, Ticho B. Alefacept is efficacious in a broad spectrum of patients with psoriasis, including those with severe disease. Poster presented at the 61st Annual Meeting of the American Academy of Dermatology; 2003 March 21-26; San Francisco, CA.
11. Langley RG, Cherman AM, Gupta AK. Alefacept: an expert review concerning the treatment of psoriasis. Exp Opin Pharmacother 2005;6:2327-33.
12. Mease PJ, Gladman DD, Keystone EC; Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo controlled study. Arthritis Rheum 2006;54:1638-45.
13. Mease PJ, Reich KE; Alefacept in Psoriatic Arthritis Study Group. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008 Nov 22.
14. Carr D, Tusa MG, Carroll CL, et al. Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatolog Treat 2008;19:97-100.
15. Parrish CA, Sobera JO, Robbins CM, et al. Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006;5:339-40.
16. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
17. Gordon KB, Valentine J. The efficacy of alefacept in the treatment of chronic plaque psoriasis. J Cutan Med Surg 2004;8 Suppl 2:3-9.
18. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.